May 2, 2017 / 8:16 PM / 3 months ago

BRIEF-Amgen, Harvard Pilgrim agree to contract for repatha

1 Min Read

May 2 (Reuters) - Amgen Inc:

* Amgen and Harvard Pilgrim agree to first cardiovascular outcomes-based refund contract for repatha (evolocumab)

* Amgen - contract provides Harvard Pilgrim with a rebate for cost of repatha for an eligible patient who has a heart attack or stroke while on repatha Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below